Literature DB >> 22162229

Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Angela L McCleary-Wheeler1, Robert McWilliams, Martin E Fernandez-Zapico.   

Abstract

Pancreatic cancer is a devastating disease with historically limited success in treatment and a poor prognosis. Pancreatic cancer appears to have a progressive pathway of development, initiating from well-described pancreatic intraepithelial neoplasia lesions and concluding with invasive carcinoma. These early lesions have been shown to harbor-specific alterations in signaling pathways that remain throughout this tumorigenesis process. Meanwhile, new alterations occur during this process of disease progression to have a cumulative effect. This series of events not only impacts the epithelial cells comprising the tumor, but they may also affect the surrounding stromal cells. The result is the formation of complex signaling networks of communication between the tumor epithelial cell and the stromal cell compartments to promote a permissive and cooperative environment. This article highlights some of the most common pathway aberrations involved with this disease, and how these may subsequently affect one or both cellular compartments. Consequently, furthering our understanding of these pathways in terms of their function on the tumoral epithelial and stromal compartments may prove to be crucial to the development of targeted and more successful therapies in the future.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22162229      PMCID: PMC3253704          DOI: 10.1002/mc.20827

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  131 in total

Review 1.  The pancreatic stellate cell: a star on the rise in pancreatic diseases.

Authors:  M Bishr Omary; Aurelia Lugea; Anson W Lowe; Stephen J Pandol
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

3.  Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.

Authors:  Irene Esposito; Hany Kayed; Shereen Keleg; Thomas Giese; E Helene Sage; Peter Schirmacher; Helmut Friess; Jörg Kleeff
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

4.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

5.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

7.  Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.

Authors:  L Huang; D Lang; J Geradts; T Obara; A J Klein-Szanto; H T Lynch; B A Ruggeri
Journal:  Mol Carcinog       Date:  1996-02       Impact factor: 4.784

8.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

9.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

View more
  22 in total

Review 1.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

3.  Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.

Authors:  Simona Dalin; Mark R Sullivan; Allison N Lau; Beatrice Grauman-Boss; Helen S Mueller; Emanuel Kreidl; Silvia Fenoglio; Alba Luengo; Jacqueline A Lees; Matthew G Vander Heiden; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cancer Res       Date:  2019-09-04       Impact factor: 12.701

4.  Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation.

Authors:  A Jesse Gore; Samantha L Deitz; Lakshmi Reddy Palam; Kelly E Craven; Murray Korc
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

5.  Increased expression of plakoglobin is associated with upregulated MAPK and PI3K/AKT signalling pathways in early resectable pancreatic ductal adenocarcinoma.

Authors:  Ekene Nweke; Monde Ntwasa; Martin Brand; John Devar; Martin Smith; Geoffrey Candy
Journal:  Oncol Lett       Date:  2020-03-23       Impact factor: 2.967

Review 6.  Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Keping Xie
Journal:  Cytokine Growth Factor Rev       Date:  2012-07-01       Impact factor: 7.638

7.  Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease.

Authors:  Stephen J Murphy; Steven N Hart; Geoffrey C Halling; Sarah H Johnson; James B Smadbeck; Travis Drucker; Joema Felipe Lima; Fariborz Rakhshan Rohakhtar; Faye R Harris; Farhad Kosari; Subbaya Subramanian; Gloria M Petersen; Timothy D Wiltshire; Benjamin R Kipp; Mark J Truty; Robert R McWilliams; Fergus J Couch; George Vasmatzis
Journal:  Cancer Res       Date:  2015-12-16       Impact factor: 12.701

8.  Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.

Authors:  Amy S Farrell; Brittany Allen-Petersen; Colin J Daniel; Xiaoyan Wang; Zhiping Wang; Sarah Rodriguez; Soren Impey; Jessica Oddo; Michael P Vitek; Charles Lopez; Dale J Christensen; Brett Sheppard; Rosalie C Sears
Journal:  Mol Cancer Res       Date:  2014-03-25       Impact factor: 5.852

9.  Role of Dietary Cancer-Preventive Phytochemicals in Pancreatic Cancer Stem Cells.

Authors:  Gaurav Kumar; Mudassir Farooqui; Chinthalapally V Rao
Journal:  Curr Pharmacol Rep       Date:  2018-06-26

10.  Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling.

Authors:  Juan Liu; Guoqing Han; Hui Liu; Chengyong Qin
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.